ienz_a_1978081_sm2219.pdf (6.57 MB)
Download file

Discovery of benzamide-hydroxypyridinone hybrids as potent multi-targeting agents for the treatment of Alzheimer's disease

Download (6.57 MB)
journal contribution
posted on 13.01.2022, 17:02 by Xiaoying Jiang, Jianan Guo, Changjun Zhang, Jinping Gu, Tao Zhou, Renren Bai, Yuanyuan Xie

A novel class of benzamide-hydroxypyridinone (HPO) derivatives were innovatively designed, synthesised, and biologically evaluated as potential multitargeting candidates for the treatment of Alzheimer's disease (AD) through pharmacophores-merged approaches based on lead compounds 18d, benzyloxy phenyl analogs, and deferiprone (DFP). These hybrids possessed potent Monoamine oxidase B (MAO-B) inhibition as well as excellent iron chelation, with pFe3+ values ranging from 18.13 to 19.39. Among all the compounds, 8g exhibited the most potent selective MAO-B inhibitor (IC50 = 68.4 nM, SI = 213). Moreover, 8g showed favourable pharmacokinetic properties and had great potential to penetrate the BBB in silico and PAMPA-BBB assay. Molecular modelling showed that 8g could adopt an extended conformation and have more enhanced interactions with MAO-B than 18d. In vitro and in vivo assays demonstrated that 8g remarkably resisted Aβ-induced oxidation and ameliorated cognitive impairment induced by scopolamine. Taken collectively, these results suggest that compound 8g is a potential multifunctional candidate for anti-AD treatment.

Funding

This project was supported by the Zhejiang Key R&D Program (No. 2021C03085), National Natural Science Foundation of China, NSFC (Grant Nos. 21576239 and 81803340), and Zhejiang Natural Science Foundation (LY20H300004).

History